Literature DB >> 10624418

Clinical problem solving based on the 1999 Canadian recommendations for the management of hypertension.

R D Feldman1, N R Campbell, P Larochelle.   

Abstract

The 1999 Canadian Recommendations for the Management of Hypertension are notable for the trends that they represent with regard to the evolution of the management of hypertension. Diagnostically, the Recommendations endorse the greater use of non-office-based measures of blood pressure control and greater emphasis on the assessment of other atherosclerotic risk factors, both when considering prognosis in hypertension and in the choice of therapy. On the treatment side of the equation, lower targets for blood pressure control have been advocated in subgroups of hypertensive patients, particularly in those with diabetes and renal disease. In conjunction with the recently published recommendations on lifestyle management, there is a greater emphasis on lifestyle modification, both as initial and adjunctive therapy in hypertension. Implicit in the recommendations for therapy is the principle that for the vast majority of hypertensive patients treated pharmacologically, practitioners should not follow a stepped-care approach. Instead, therapy should be individualized, primarily based on consideration of concurrent diseases, both cardiovascular and noncardiovascular (Tables 1 and 2). Through the consensus process, there was a general appreciation of how far we have come in the development of evidence-based recommendations for hypertension management. However, there was also an increasing appreciation of how far we have to go in effectively translating these recommendations into better blood pressure control.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10624418      PMCID: PMC1253507     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  130 in total

1.  An updated coronary risk profile. A statement for health professionals.

Authors:  K M Anderson; P W Wilson; P M Odell; W B Kannel
Journal:  Circulation       Date:  1991-01       Impact factor: 29.690

2.  Recommendations for the use of home (self) and ambulatory blood pressure monitoring. American Society of Hypertension Ad Hoc Panel.

Authors:  T Pickering
Journal:  Am J Hypertens       Date:  1996-01       Impact factor: 2.689

3.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

Authors:  J A Staessen; R Fagard; L Thijs; H Celis; G G Arabidze; W H Birkenhäger; C J Bulpitt; P W de Leeuw; C T Dollery; A E Fletcher; F Forette; G Leonetti; C Nachev; E T O'Brien; J Rosenfeld; J L Rodicio; J Tuomilehto; A Zanchetti
Journal:  Lancet       Date:  1997-09-13       Impact factor: 79.321

Review 4.  Atherosclerosis and urate metabolism.

Authors:  B T Emmerson
Journal:  Aust N Z J Med       Date:  1979-08

5.  Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group.

Authors:  J N Cohn; S Ziesche; R Smith; I Anand; W B Dunkman; H Loeb; G Cintron; W Boden; L Baruch; P Rochin; L Loss
Journal:  Circulation       Date:  1997-08-05       Impact factor: 29.690

6.  Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group.

Authors:  M Packer; C M O'Connor; J K Ghali; M L Pressler; P E Carson; R N Belkin; A B Miller; G W Neuberg; D Frid; J H Wertheimer; A B Cropp; D L DeMets
Journal:  N Engl J Med       Date:  1996-10-10       Impact factor: 91.245

7.  Self-recording of blood pressure in the management of hypertension.

Authors:  A L Johnson; D W Taylor; D L Sackett; C W Dunnett; A G Shimizu
Journal:  Can Med Assoc J       Date:  1978-11-04       Impact factor: 8.262

8.  Difficulties in diagnosing hypertension: implications and alternatives.

Authors:  H M Perry; J P Miller
Journal:  J Hypertens       Date:  1992-08       Impact factor: 4.844

9.  The influence of chronic treatment with betablockade and angiotensin converting enzyme inhibition on the peripheral blood flow in hypertensive patients with and without concomitant intermittent claudication. A comparative cross-over trial.

Authors:  L L Van de Ven; J T Van Leeuwen; A J Smit
Journal:  Vasa       Date:  1994       Impact factor: 1.961

10.  Should echocardiography be performed to assess effects of antihypertensive therapy? Test-retest reliability of echocardiography for measurement of left ventricular mass and function.

Authors:  J S Gottdiener; S V Livengood; P S Meyer; G A Chase
Journal:  J Am Coll Cardiol       Date:  1995-02       Impact factor: 24.094

View more
  2 in total

Review 1.  Canadian Hypertension Education Program: the evolution of hypertension management guidelines in Canada.

Authors:  Ross D Feldman; Norman R C Campbell; Katherine Wyard
Journal:  Can J Cardiol       Date:  2008-06       Impact factor: 5.223

2.  Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data.

Authors:  J-L Chiasson; R G Josse; R Gomis; M Hanefeld; A Karasik; M Laakso
Journal:  Diabetologia       Date:  2004-05-26       Impact factor: 10.122

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.